Maravai Lifesciences Holdings (MRVI) Asset Utilization Ratio (2021 - 2026)
Maravai Lifesciences Holdings (MRVI) posted quarterly Asset Utilization Ratio of 0.28 for Q1 2026, up 12.27% year-over-year from 0.25 in Q1 2025, and up 20.32% quarter-over-quarter from 0.23 in Q4 2025.
Maravai Lifesciences Holdings (MRVI) Asset Utilization Ratio (2021 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' Asset Utilization Ratio history runs 6 years deep, the most recent figure standing at 0.28 for Q1 2026.
- In Q1 2026, Asset Utilization Ratio rose 12.27% year-over-year to 0.28; the TTM figure through Mar 2026 stood at 0.28 (up 12.27% YoY), while the FY2025 annual figure was 0.21, up 0.55% from the prior year.
- Asset Utilization Ratio for Q1 2026 stood at 0.28, up from 0.23 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 0.45 in Q1 2022, with the low at 0.15 in Q4 2023.
- The 5-year median for Asset Utilization Ratio is 0.24 (2025), against an average of 0.27.
- The sharpest annual moves came in 2022 and 2023: Asset Utilization Ratio jumped 55.43% in 2022, then sank 60.51% in 2023.
- Maravai Lifesciences Holdings' Asset Utilization Ratio stood at 0.39 in 2022, then slumped by 60.51% to 0.15 in 2023, then soared by 47.31% to 0.23 in 2024, then rose by 1.16% to 0.23 in 2025, then increased by 20.32% to 0.28 in 2026.
- Business Quant data shows MRVI's Asset Utilization Ratio at 0.28 in Q1 2026, 0.23 in Q4 2025, and 0.22 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | Maravai Lifesciences Holdings | 1.48 Bn | 1.56 Bn | 20.65 Mn | 0.32 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.32 |
| Mar 31, 2026 | 0.28 |
| Dec 31, 2025 | 0.23 |
| Sep 30, 2025 | 0.22 |
| Jun 30, 2025 | 0.24 |
| Mar 31, 2025 | 0.25 |
| Dec 31, 2024 | 0.23 |
| Sep 30, 2024 | 0.20 |
| Jun 30, 2024 | 0.19 |
| Mar 31, 2024 | 0.19 |
| Dec 31, 2023 | 0.15 |
| Sep 30, 2023 | 0.19 |
| Jun 30, 2023 | 0.24 |
| Mar 31, 2023 | 0.31 |
| Dec 31, 2022 | 0.39 |
| Sep 30, 2022 | 0.41 |
| Jun 30, 2022 | 0.44 |
| Mar 31, 2022 | 0.45 |
| Dec 31, 2021 | 0.42 |
| Sep 30, 2021 | 0.38 |